Astellas Pharma Aktie
| 9,53EUR | 0,08EUR | 0,85% |
WKN: 856273 / ISIN: JP3942400007
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 95,70 |
| BlackRock Fund Advisors | 3,43 |
| Nippon Life Insurance Co. | 2,85 |
| Nomura Asset NEXT FUNDS TOPIX ETF (1306) | 2,84 |
| Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) | 2,46 |
| BlackRock Japan Co. Ltd. | 2,10 |
| Mitsubishi UFJ Asset Management Co., Ltd. | 1,58 |
| Vanguard Health Care Fund | 1,57 |
| Government Pension Fund - Global (The) | 1,53 |
| Vanguard Total International Stock Index Fund | 1,38 |
| Astellas Pharma Director Incentive Plan | 0,88 |
| BlackRock Advisors (UK) Ltd. | 0,82 |
| BlackRock Investment Management (UK) Ltd. | 0,51 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 15 883 | 15 455 | 14 522 | 14 484 | 14 754 |
| Umsatz pro Mitarbeiter in Mio. EUR | 81,90 | 80,85 | 89,26 | 104,85 | 108,69 |
Bilanz (in Mio. JPY) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 867 514 | 872 588 | 923 354 | 1 049 954 | 1 194 730 |
| Summe Anlagevermögen | 1 450 646 | 1 401 040 | 1 409 041 | 1 406 564 | 2 374 873 |
| Summe Aktiva | 2 318 160 | 2 273 628 | 2 332 395 | 2 456 518 | 3 569 603 |
Bilanz (in Mio. JPY) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 413 332 | 278 264 | 212 744 | 200 007 | 1 005 716 |
| Summe Fremdkapital | 1 028 990 | 887 514 | 872 086 | 948 564 | 1 973 616 |
| Summe Eigenkapital | 1 289 168 | 1 386 115 | 1 460 308 | 1 507 954 | 1 595 988 |
| Summe Passiva | 2 318 158 | 2 273 629 | 2 332 394 | 2 456 518 | 3 569 604 |
Adresse
| 2-5-1 Nihonbashi-Honcho, 103-8411 Tokyo | |
| Telefon | +81 (3) 3244-3000 |
| Internet | https://www.astellas.com/jp/ |
Management
|
Adam John Pearson
Chief Strategy Officer |
|
Atsushi Kamide
Manager-Public Relations |
|
Catherine Levitt
General Counsel |
|
Claudia Mitchell
Senior VP-Product & Portfolio Strategy |
|
Claus Gerhard Zieler
Chief Commercial Officer |
|
Eriko Sakurai
Outside Director |
|
Haruko Shibumura
Outside Director |
|
Hideki Shima
Chief Manufacturing Officer |
|
Hideto Yamaguchi
Senior Director-Pharmaceutical Technologies |
|
Hiroko Sakai
Director |
|
Hiroo Sasaki
Outside Director |
|
Hiroshi Kawabe
Independent Outside Director |
|
Katsuyoshi Sugita
EVP, Chief People, Ethics & Compliance Officer |
|
Kazunori Maruyama
Director-Innovation Management |
|
Kei Motonaga
Sr Dir-Quality Control Div, Yaizu Technology Ctr |
|
Keisuke Mitsuoka
Associate Director |
|
Kenji Yasukawa
Chairman |
|
Kitamura Atsushi
Chief Financial Officer |
|
Luiz Dutra
Managing Director-Astellas Farma Brasil |
|
Mamoru Sekiyama
Independent Outside Director |
|
Masahide Goto
President-Astellas Institute-Regenerative Medicine |
|
Mika Nakayama
Outside Director |
|
Naoki Okamura
President, CEO & Representative Director |
|
Nick Eshkenazi
Chief Digital & Transformation Officer |
|
Nobuaki Tanaka
Senior Executive Officer & General Manager-Sales |
|
Nobue Yasuda
Manager-Accounting |
|
Noriyuki Uematsu
Outside Director |
|
Peter Sandor
VP, Head-Oncology Therapeutic Area in Mktg Strat |
|
Ryosuke Munakata
Director |
|
SUMIHO NAKATSU
Associate Manager |
|
Shigeru Nakaji
Exec Dir-Japan-Asia Clinical Dev 1, Dev |
|
Tadaaki Taniguchi
Chief Medical Officer |
|
Takashi Tanaka
Outside Director |
|
Taro Masunaga
Exec Dir-Incubation Rsch Labs, Drug Discovery Rsch |
|
Tatsuro Ishizuka
Independent Outside Director |
|
Tomokazu Fujisawa
Director |
|
Tomoyuki Yasunaga
Staff Exec Dir-Plnng & Admin-Drug Discovery Rsch |
|
Tyler Marciniak
Director-Oncology Communications & Advocacy |
|
Yoshitsugu Shitaka
Chief Scientific Officer & Head-Research |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
